KR20220149718A - L-에르고티오네인 함유 조성물 - Google Patents

L-에르고티오네인 함유 조성물 Download PDF

Info

Publication number
KR20220149718A
KR20220149718A KR1020227033764A KR20227033764A KR20220149718A KR 20220149718 A KR20220149718 A KR 20220149718A KR 1020227033764 A KR1020227033764 A KR 1020227033764A KR 20227033764 A KR20227033764 A KR 20227033764A KR 20220149718 A KR20220149718 A KR 20220149718A
Authority
KR
South Korea
Prior art keywords
egt
dth
composition
mass
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227033764A
Other languages
English (en)
Korean (ko)
Inventor
타케시 나카타니
나오미 나카시마
Original Assignee
나가세 상교오 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나가세 상교오 가부시키가이샤 filed Critical 나가세 상교오 가부시키가이샤
Publication of KR20220149718A publication Critical patent/KR20220149718A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020227033764A 2020-03-04 2021-03-04 L-에르고티오네인 함유 조성물 Pending KR20220149718A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-036577 2020-03-04
JP2020036577A JP6864131B1 (ja) 2020-03-04 2020-03-04 Ｌ−エルゴチオネイン含有組成物
PCT/JP2021/008388 WO2021177397A1 (ja) 2020-03-04 2021-03-04 Ｌ－エルゴチオネイン含有組成物

Publications (1)

Publication Number Publication Date
KR20220149718A true KR20220149718A (ko) 2022-11-08

Family

ID=75638746

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227033764A Pending KR20220149718A (ko) 2020-03-04 2021-03-04 L-에르고티오네인 함유 조성물

Country Status (8)

Country Link
US (1) US12357614B2 (https=)
EP (1) EP4115881A4 (https=)
JP (3) JP6864131B1 (https=)
KR (1) KR20220149718A (https=)
CN (1) CN115209895A (https=)
CA (1) CA3170408A1 (https=)
TW (1) TW202146013A (https=)
WO (1) WO2021177397A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118215476A (zh) * 2021-11-08 2024-06-18 三菱瓦斯化学株式会社 用于抑制或预防内耳性耳聋的含有麦角硫因的组合物
KR20240127428A (ko) * 2021-12-23 2024-08-22 산토리 홀딩스 가부시키가이샤 경구 조성물 및 소프트 캡슐제
CN121311472A (zh) * 2023-06-15 2026-01-09 长濑产业株式会社 化合物或其盐及其制造方法、组合物、过氧化氢清除剂以及细胞毒性抑制剂
WO2025142813A1 (ja) * 2023-12-27 2025-07-03 サントリーホールディングス株式会社 経口組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019089878A1 (en) 2017-11-02 2019-05-09 Colorado Seminary, Owner and Operator of University of Denver Methods of treating microbial infection and inflammation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707086A1 (fr) * 1993-06-28 1995-01-06 Bioxytech Procédé de préparation de l'ergothionéine.
DE102004020714A1 (de) * 2004-04-26 2005-11-10 Beiersdorf Ag Haut- und/oder Haarmittel enthaltend Verbindungen mit isoprenoider Struktur
FR2910808B1 (fr) * 2006-12-29 2009-04-10 Lvmh Rech Utilisation en cosmetique de la l-2-thiohistidine ou d'un de ses derives comme agent depigmentant.
US7767826B2 (en) 2007-10-05 2010-08-03 Pharmatech International, Inc. Process for the synthesis of L-(+)-ergothioneine
JP2009126863A (ja) * 2007-11-27 2009-06-11 Koei Kogyo Kk キノコから抽出したエルゴチオネインを高含有する組成物
FR2950889B1 (fr) * 2009-10-06 2011-11-18 Tetrahedron Procede de synthese de l'ergothioneine et analogues
FR2950890B1 (fr) * 2009-10-06 2011-12-30 Tetrahedron Procede de synthese de la 2-thiohistidine et analogues
AU2013234815B2 (en) 2012-03-23 2017-06-22 The University Of Queensland Immunomodulatory agent and uses therefor
GB201416678D0 (en) * 2014-09-22 2014-11-05 Univ Cape Town Process For Synthesizing Ergothioneine And Its Intermediates
EP3252142B1 (en) * 2015-01-30 2021-11-03 Kikkoman Corporation Transformed fungus having enhanced ergothioneine productivity and method for producing ergothioneine
US11098330B2 (en) 2018-02-23 2021-08-24 Nagase & Co., Ltd. Method for producing ergothioneine
JP7185213B2 (ja) * 2018-03-02 2022-12-07 国立大学法人 筑波大学 エルゴチオネイン合成微生物、及びエルゴチオネインの製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019089878A1 (en) 2017-11-02 2019-05-09 Colorado Seminary, Owner and Operator of University of Denver Methods of treating microbial infection and inflammation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PLoS ONE 12(1): e0169360
S. Yoshida et al., Front. Immunol.10: 671(2019)
Tamagawa University Faculty of Agriculture Research and Education Proceedings No. 1: 17-41 (2016)

Also Published As

Publication number Publication date
JPWO2021177397A1 (https=) 2021-09-10
CA3170408A1 (en) 2021-09-10
CN115209895A (zh) 2022-10-18
JP6864131B1 (ja) 2021-04-28
JP2021138640A (ja) 2021-09-16
EP4115881A4 (en) 2024-04-03
EP4115881A1 (en) 2023-01-11
TW202146013A (zh) 2021-12-16
BR112022017415A2 (pt) 2022-10-18
JP2026021447A (ja) 2026-02-10
WO2021177397A1 (ja) 2021-09-10
US12357614B2 (en) 2025-07-15
US20230126387A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
US12357614B2 (en) L-ergothioneine-containing composition
KR101850711B1 (ko) 피부주름 개선 및 탄력 증진용 조성물
KR20150057917A (ko) 피부 미백용 조성물
JP2011032171A (ja) 美白用組成物
KR102139659B1 (ko) 피부 개선용 조성물
JP4828922B2 (ja) 抗アレルギー剤
KR102124986B1 (ko) 익모초 추출물 또는 레오누린을 함유하는 근육 질환 예방 또는 치료용 또는 근 기능 개선용 조성물
US7622450B2 (en) Flavone C-glycoside derivatives and compositions containing the derivatives
KR102496282B1 (ko) 사이토칼라신 d 또는 sag를 포함하는 항노화용 조성물 및 항노화 물질 스크리닝 방법
EP4324336B1 (en) L-ergothioneine-containing composition
BR122023019667B1 (pt) Método de produção de uma composição contendo l-ergotioneína e n, n-dimetil-l-2-tiohistidina e método de supressão de coloração da composição
BR112022017415B1 (pt) Composição contendo l-ergotioneína
JP7727671B2 (ja) ホモシステイン誘導体及びその製造方法、組成物、並びに、炎症抑制剤
HK40075066A (en) L-ergothioneine-containing composition
KR20210101159A (ko) 릴메니딘 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
KR20150019678A (ko) 피부 미백용 조성물
KR101356213B1 (ko) 노다케닌을 포함하는 알레르기 질환 예방 또는 치료용 조성물
KR20200123688A (ko) 약쑥을 함유하는 근육 질환 예방 및 치료용 또는 근 기능 개선용 조성물
KR102138263B1 (ko) 피부 재생 또는 주름 개선용 조성물
KR20170098182A (ko) 알레르기성 또는 염증성 피부질환의 예방 또는 치료용 조성물
KR20150019675A (ko) 피부 미백용 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902